Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ: MLTX )

42.73 +0.10 (+0.23%)
Streaming Delayed Price Updated: 11:30 AM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MoonLake Immunotherapeutics - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
From Komodo Health
Via Business Wire
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
The company tested its psoriatic arthritis drug over 24 weeks against Humira. 
Via Investor's Business Daily
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors. 
Via Benzinga
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Expert Ratings for MoonLake
Via Benzinga
Recap: MoonLake Q3 Earnings
Via Benzinga
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
16 Analysts Have This to Say About MoonLake
Via Benzinga
Where MoonLake Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements. 
Via Investor's Business Daily
Dow Turns Lower; EchoStar Shares Plunge
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... 
Via Benzinga
Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today?
Sunday, MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with  
Via Benzinga
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Rise; Nasdaq Gains 50 Points
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday Following the market opening Monday, the Dow traded up 0.21% to 34,133.62 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week... 
Via Benzinga
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update. 
Via Investor's Business Daily
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
From MoonLake Immunotherapeutics AG
Via GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.